Vistagen Therapeutics (VTGN) Total Debt Growth (3y) (2014 - 2026)
Vistagen Therapeutics (VTGN) Total Debt Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.08% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.52% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -22.87% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.30% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.76% |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.71% |
| Jun 30, 2023 | 12.31% |
| Mar 31, 2023 | -2.33% |
| Dec 31, 2022 | 81.15% |
| Sep 30, 2022 | 66.10% |
| Jun 30, 2022 | 61.49% |
| Dec 31, 2020 | 31.07% |
| Sep 30, 2020 | 61.11% |
| Jun 30, 2020 | 49.55% |
| Mar 31, 2020 | 1.02% |
| Dec 31, 2019 | 25.34% |
| Mar 31, 2019 | 0.06% |
| Dec 31, 2017 | -78.34% |
| Mar 31, 2017 | 212.25% |
| Dec 31, 2016 | 51.48% |
| Mar 31, 2016 | 216.74% |
| Mar 31, 2014 | -71.82% |